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Keratoacanthoma (KA) is a benign keratinocytic neoplasm that spontaneously regresses after 3–6 months and
shares features with squamous cell carcinomas (SCCs). Furthermore, there are reports of KAs that have
metastasized, invoking the question of whether KA is a variant of SCC (Hodak et al., 1993). To date, no reported
criteria are sensitive enough to discriminate reliably between KA and SCC, and consequently there is
a clinical need for discriminating markers. Our previous study analyzed 132 KAs and 29 SCCs and revealed
significantly different regions of genomic aberrations using chromosomal comparative genomic hybridization
(CGH). In the present study, we applied array CGH to investigate 98 KAs and 22 SCCs from the above samples.
The result shows that all KAs and SCCs have some degree of genetic aberrations. The distribution of numbers of
aberrant clones per sample differed significantly between KAs and SCCs (Po0.02), which also demonstrated
recurrent aberrations that differed significantly (Po0.001), as illustrated by unsupervised cluster analysis.
Classifiers for clinicopathological parameters of KAs were established based on t-test statistics and permutation
tests. Tumor size, fibrosis, and inflammation, which are related to the developmental stages of KAs, showed
significant (t-test, permutation test) associations with aberrations of selected genomic regions. This suggests
chromosomal instability during the whole life cycle of KAs.
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INTRODUCTION
Keratoacanthoma (KA) is a common, unique benign kerati-
nocytic neoplasm that usually presents as a solitary nodule
developing a central keratin-filled crater. The lesion is usually
located on sun-exposed areas of the skin of elderly persons. It
mostly develops within 6–8 weeks, with spontaneous regres-
sion after 3–6 months, although much longer life spans are
also observed. Thus, KAs typically evolve in three clinical
stages: the proliferative, maturing, and resolving stage. KAs
may appear as multiple lesions (Grzybowski, 1950; Muir
et al., 1967; Ferguson-Smith et al., 1971), and the incidence
is increased among immunosuppressed patients (Sullivan and
Colditz, 1979). The histopathological diagnosis of KA is
based on the architecture and on cytologic features, and
when a typical clinical history is known most KAs can be
distinguished from squamous cell carcinomas (SCCs) (Elder
et al., 1997; Weedon, 2003). However, particularly in the
early proliferative phase, KA shares features with SCC such as
infiltration and cytological atypia and is considered by some
to be an abortive or self-healing malignancy (Schwartz,
1994). However, the literature also reports KAs that have
metastasized, raising the question of whether KA is a variant
of SCC (Hodak et al., 1993). The discussions on this issue
of KAs are still ongoing (Schwartz, 2004; Karaa and
Khachemoune, 2007; Mandrell and Santa Cruz, 2009;
Ko, 2010; Weedon et al., 2010a).
So far, there are no criteria that are sensitive enough to
discriminate reliably between KA and SCC (Kerschmann
et al., 1994; Quinn et al., 1994; Cribier et al., 1999; Jensen
et al., 1999; Putti et al., 2004). There is thus a clinical need
for markers that may distinguish between the two entities.
Previously, Clausen et al. (2002, 2006) found, by means
of comparative genomic hybridization (CGH), that about
one-third of KAs harbored genomic aberrations, and that
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cutaneous SCCs had a significantly higher degree of
chromosomal aberrations, and thus chromosomal instability,
than KAs.
Array-based CGH (array CGH) is a global DNA analysis
method where labeled DNA fragments are hybridized to
arrays of bacterial artificial chromosome (BAC) clones instead
of metaphase chromosomes, as used in the conventional
CGH method (Snijders et al., 2001). The 1-Mb-resolution
BAC clone set used in the present study comprises 3,340
clones, and is a much more sensitive method for screening
genomic aberrations than conventional CGH.
The aim of the present study was 2-fold. First, we wanted
to characterize genomic aberrations with the more sensitive
technique array CGH in different developmental stages and
categories of KAs. Second, we wanted to compare genetic
aberrations found in KAs and SCCs to analyze whether the
two types of neoplasia are interrelated or whether they
constitute two separate entities.
RESULTS
Clinicopathological description of KAs is shown in Supple-
mentary Table S1 online. All analyzed samples of KAs, as
well as of SCCs, harbored genetic aberrations when analyzed
by array CGH (Supplementary Table S2 online). An overview
of the genetic aberration profiles for all chromosomes
except for Y is shown for KAs in Figure 1a, and for SCCs in
Figure 1b. Regions with gains (dark gray and above the zero
line), as well as with losses (light gray and below the zero
line), are to a large extent overlapping for KAs and SCCs.
However, there are also obvious differences in the patterns of
aberrations between the two types of neoplasms—as seen
most clearly on chromosomes 7, 8, and 10. The size of
the regions with detected aberrations was summed up for
each tumor, and the means for KAs and SCCs were found
to constitute 17.2% and 24.9% of the whole genome,
respectively. In Figure 2, KAs and SCCs show two main
clusters in a dendrogram using unsupervised cluster analysis,
also demonstrating that the aberration profiles of these two
types of lesions are significantly different (Fisher’s exact test,
Po0.001). The same tendency of differential distribution of
KAs and SCCs in the dendrogram is also seen in pvclust
analysis (Fisher’s exact test, P¼0.02903) (Supplementary
Figure S1 online). Furthermore, the aberrant clone numbers
per sample in the two types of neoplasms were significantly
different (Wilcox–Man–Whitney test, Po0.02), with the
majority of KAs having fewer aberrant clones as illustrated
in Figure 3. However, some large recurrent aberrations in
KAs were found (Supplementary Table S3 online). Most of
chromosome 19 (19p13.3–19q13.43) was lost in 37% of the
cases, and gains of most of chromosome X (Xp22.33–Xq28)
were found in a similar number of cases. Large aberrations
(gain) were also found in chromosome 20 (20p13–20q13.33)
in 34% of the cases. In the SCCs, gains in 8q11.22–8q24.3,
7p22.2–7q36.3, and Xp22.33-Xq28 were detected in 35%,
34%, and 35% of the cases, respectively, whereas losses in
10p15.3–10q26.3 and13q12.11–13q34 were detected in 34%
and 38% of the cases, respectively (Supplementary Table S3
online).
Chromosomal region 17p13.3–17q25.3 was lost in 27% of
the cases of KAs. The same region was lost in 46% of the
SCCs. The important tumor suppressor gene, TP53, is located
in these regions, and we have recently shown (Durinck et al.,
2011) that loss of functional TP53 is one of the earliest and
most crucial steps in the development of malignant cuta-
neous SCCs. Thus, we analyzed the TP53 region in more
detail. In the BAC clone set, we identified two overlapping
BAC clones (RP11-199F11, chr17, 7438479–7599079; RP11-
404G1, chr17, 7563870–7733801) as reflecting the copy
number variations for TP53, as TP53 is located in these two
BAC clones (17p13.1). According to the copy number status
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Figure 1. Profiles of genetic aberrations. (a) Keratoacanthomas and (b) squamous cell carcinomas along all chromosomes with the exception of chromosome
Y; dark gray (above the zero line) indicates amplification and light gray (below the zero line) indicates loss. Note differences between the two types of lesions
within chromosomes 7, 8, and 10.
www.jidonline.org 2061
J Li et al.
Array Comparative Genomic Hybridization
of these two BAC clones, we classified KAs and SCCs into
four groups: KA with TP53 deletion (n¼ 28), KA without
TP53 deletion (n¼64), SCC with TP53 deletion (n¼11), and
SCC without TP53 deletion (n¼11). The mean of the total
aberration percentage values for each group is as follows:
KA with TP53 deletion (18.77%), KA without TP53 deletion
(15.59%), SCC with TP53 deletion (32.49%), and SCC
without TP53 deletion (17.29%). The values of aberration
percentage are not normally distributed for the KA groups
(overrepresentation of cases with very few or relatively many
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Figure 2. Unsupervised cluster analysis of squamous cell carcinomas (SCCs) and keratoacanthomas (KAs). Losses are indicated by red and gains by green.
The aberration profiles of KAs and SCCs are significantly different (Fisher’s exact test, Po0.001).
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aberrations) but logarithmic transformation of all data
allowed Welch t-tests for significant differences in mean
aberration values between groups. KAs with and without
TP53 deletion are significantly different in this respect
(Po0.0234) and so are SCCs with and without TP53 deletion
(Po0.0192). Furthermore, the mean aberration value in the
group of SCC with TP53 deletion was larger than in the group
of KAs with TP53 deletion (Po0.0117).
A number of genomic aberrations were revealed by clones
that would predict a lesion as either of the two entities. The
best predictor (combination of clones) showed an accuracy of
85% (Fisher’s exact test, Po0.013). There were 87 predictor
clones, the majority of which were located on chromosomes
7 and 10, plus a minority on chromosome 8 (see Supple-
mentary Table S4 online). We also made a supervised
comparison between KAs with high-grade atypia (þ þ þ )
and SCCs, identifying three regions that can distinguish
the two types of neoplasms, namely 10p15.3–10q21.3,
10q26.13–10q26.3, and 13q12.2–13q14.12.
Within the present study, the keratoacanthomas were
classified according to their developmental stages in two
ways. First, young (proliferating) and old (regressing) lesions
were differentiated based on their age in weeks as estimated
by the patients. Second, the degree of fibrosis and inflamma-
tion, which are associated with older lesions, was used to
characterize the developmental stage. We also recorded the
degree of infiltrating growth and the degree of atypia (both
features shared by SCCs), the size of the lesions, and their
HPV status. All these parameters were analyzed for associa-
tion with the observed genetic aberrations of the KAs by t-test
statistic analysis and permutation testing. No significant
correlations were revealed between genetic aberrations and
the degree of atypia, the degree of infiltration, or the esti-
mated age of the lesions. Lesions with increased inflamma-
tion had a higher number of aberrations involving clones
representing 10q23.1–10q23.32 and 13q12.11–13q32.1,
whereas lesions with high levels of fibrosis selected for
3p24.3–3p14.3, and lesions with large tumor size selected
for 3p26.3–3p26.1, 3p25.3–3p24.3 and 3p24.1–3q25.3
clones. HPV positivity was seen in 43 of the 75 analyzed
samples (57%) and selected for several clones located
on chromosome 4 (4q22.3–4q32.1 and 4q32.2–4q35.2).
Furthermore, the KAs with high level of fibrosis show larger
tumor size than those with low level of fibrosis (Fisher’s
exact test, Po0.008). There were no significant differences
in genomic aberrations between lesions from transplanted
(77) patients (immune-suppressed) and non-transplanted
(21) patients.
DISCUSSION
It is well known that KAs, as well as SCCs, develop preferen-
tially on sun-exposed areas of the skin, and that actinic
keratosis as a result of sun damage is a precursor lesion for
SCC (Elder et al., 1997). The reported frequencies of
malignant transformation within actinic keratosis lesions are
debated, but recent data indicate a significant frequency of
transformation, possibly 410% (Mittelbronn et al., 1998). It
is also reported that numerous chromosomal aberrations are
shared by actinic keratosis and SCCs (Ashton et al., 2003),
consistent with the former lesion being a precursor. No such
precursor lesion has been recognized for KAs, which
(contrary to SCCs) show complete regression in practically
all cases (Weedon, 2003). Despite these facts, and as there
are reports of KAs giving rise to metastases, there is still a
discussion whether KA is a variant of SCC (Schwartz, 2004;
Karaa and Khachemoune, 2007; Ko, 2010; Weedon et al.,
2010a). In many cases it is difficult, especially in biopsies, to
distinguish between KAs and SCCs because they share
malignant features such as infiltration and atypia. Thus, it
would be clinically helpful to define genetic differences that
more objectively may separate the two lesions, as they
require different treatments and follow-up.
In the present study, based on array CGH, all KAs were
found to have detectable copy number aberrations, including
the KAs (about 2/3 of the cases) that in a previous study did
not show aberrations by chromosome CGH (Clausen et al.,
2006). This reflects the considerably higher resolution of the
array method.
Recurrent aberrations, particularly on chromosomes 17,
19, 20, and X, were observed in about 1/3 of the KAs. The
recurrently aberrant regions might harbor genes of particular
importance for the biological features of KAs. Compared with
our previous results on CGH of the same samples of KAs, the
distribution of aberrations along the genome is in general
similar, although the aberrations that recur most frequently
were different. This is not surprising, as three times as many
lesions were detected by array CGH, and, furthermore,
seemingly simple gains and losses revealed by chromosome
CGH have proven to consist of complex discontinuous sets of
aberrations only deciphered by the high-resolution technol-
ogies (Kallioniemi, 2008).
Cytological atypia is seen in many KAs—a feature shared
with SCCs. We therefore scored the degree of atypia to check
whether the subgroup with atypia had certain characteristics
different from lesions with less or without atypia. We did not
find any differences in genetic aberrations between the groups.
Furthermore, by supervised comparison between KAs with
high-grade atypia (þ þ þ ) and SCC, three distinguishing
genomic regions were identified, namely 10p15.3–10q21.3,
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10q26.13–10q26.3, and 13q12.2–13q14.12. This strongly
suggests that KAs with or without atypia belong to the same
subgroup, and that KAs with high-grade atypia should not be
classified as SCCs based on this feature alone.
Infiltration is another feature shared between KA and SCC.
There were no significant differences in genomic aberrations
between KAs with little or without infiltration and those with
high degree of infiltration, suggesting that this feature is
consistent with the diagnosis of KA.
In all, 57% of KAs that were analyzed with respect to
cutaneous and genital HPV types in the present study
harbored cutaneous HPV types (Forslund et al., 2003). In
the present study, an association between genetic aberrations
and HPV positivity was found, with the majority of selected
BAC clones located on chromosome 4. Such an association
is consistent with a role of HPV during KA development.
However, no predominant HPV type was found in the
previous study (Forslund et al., 2003), which might make it
less likely that HPV is causally involved in KA development.
There are three clinical stages in the typical natural history
of KAs: a proliferative, maturing, and resolving stage. We
have tried to characterize the stage of lesions based on the
age in weeks as estimated by the patient, as well as by
histopathological criteria (i.e., the degree of fibrosis and/or
inflammation). No associations were found between the age
in weeks and genetic aberrations or HPV status, respectively.
However, the degree of fibrosis was associated with
aberrations on chromosome 3 (3p24.3–3p14.3), and the
degree of inflammation was associated with aberrations
on chromosomes 10 (10q23.1–10q23.32) and 13 (13q12.11–
13q32.1). As fibrosis and inflammation are correlated with
the developmental stage, and thus the age of KAs, this result
suggests that the progression of KAs may be associated with
chromosomal instability and genetic changes throughout the
different developmental stages. It may also indicate that more
objective, histopathological criteria are better indicators of
developmental stages than age estimations in weeks. How-
ever, the discrepant results may also mean that there are
substantial variations in the natural length of the develop-
mental cycle of KAs. The fact that the size of lesions was
correlated with aberrations on chromosome 3 (some of which
being the same as those selected for by fibrosis) is consistent
with the finding that size and fibrosis are significantly
associated, and that both are correlated with the late
developmental stage of KAs.
Only about 16% of the analyzed SCCs failed to show
genetic aberrations by chromosome CGH (Clausen et al.,
2006), and array CGH analysis reduced this fraction to zero.
Recurring aberrations were found in 440% of SCCs on
chromosomes 7, 8, 10, 13, 17, and X, with losses on certain
regions of 17p and 17q recurring in 450% of samples. We
have found one report in the literature on array CGH of
cutaneous SCCs, showing results from eight analyzed cases,
two of which were classified as crateriform/keratoacantho-
ma-like SCCs (Salgado et al., 2008). The number of cases in
that study is too small to provide reliable information on
recurrent aberrations, but aberrations were found on chromo-
somes 7, 8, 13, and X, which was consistent with our results.
Using chromosome CGH, recurrent aberrations in cutaneous
SCCs were reported on chromosomes 7, 8, 17, and X by
Ashton et al., 2003, and aberrations on chromosome 8, 17,
and X also were reported by CGH of SCCs in a review
(Baudis, 2007). It is therefore reasonable to assume that
aberrant genes within these recurrent regions may be
determinants for the development and progression of SCCs.
Recurrent aberrations on chromosomes 7, 8, 10, and 13 were
not recorded in KAs, implying that genes within these regions
may be responsible for the progressive growth and inability of
SCCs to regress. Many aberrant genes responsible for
promotion of growth and infiltration may be common for
KAs and SCCs, whereas genetic aberrations promoting or
making apoptosis possible have to be sought among genomic
areas recurrently occurring in KAs. Candidates for such
genes may be found within amplifications on chromosome X
(e.g., apoptosis-inducing factor 1 and tumor necrosis factor
receptor superfamily) and within amplifications on chromo-
some 20 (e.g., Bcl-X, death associated transcription factor 1,
and retinoblastoma protein 1). The anti-apoptotic Bcl-xL
protein was found to be present in 84% of SCCs compared
with only 15% in KAs (Po0.001) (Vasiljevic et al., 2009),
suggesting a possible role for the anti-apoptotic Bcl-xL
protein for progression and lack of regression in SCCs, and
for a possible role of apoptosis in the regression of KA.
The difference in aberration patterns between KA and SCC
is significant (Fisher’s exact Po0.001) and is illustrated by the
unsupervised cluster analysis in Figure 2. This is consistent
with recurrent aberrations within the two types of lesions also
being different, supporting the previous assumption that these
lesions are separate entities (Clausen et al., 2006). Our
supervised cluster analysis could predict the correct classi-
fication of a lesion to an accuracy of 85% (Po0.013). The
BAC clones (total 87 clones) of the best predictor were
located on chromosomes 7, 8, and 10. This includes chromo-
somal regions in which many recurrent aberrations in SCCs
are located, indicating that these genes, at least partly, may
abrogate pathways for induction of apoptosis, or activate
pathways for continuous cell proliferation and infiltration.
Examples of candidate genes affected within these regions are
CDC2 (cell division control protein), which appears to be
deleted on chromosome 10, and GTF 21 (general transcrip-
tion factor II-I), STYXL1 (Map kinase phosphatase–like protein
MKSTYX), and TP53AP1 (TP53 activated protein), which all
seem to be amplified on chromosome 7.
The TP53 gene itself is of special interest in cutaneous
epithelial carcinogenesis. Loss of the wild-type allele seems
to be one of the earliest events in the evolutionary history
of SCCs and demarcate a key transition in the progression
toward cancer by unleashing broad genomic instability
(Durinck et al., 2011). In SCCs, loss of wild-type TP53
frequently occurs by mutation of one allele followed by copy
neutral loss of heterozygosity. This form of uniparental
disomy of the mutated TP53 region may represent a need
to maintain some genes in diploid copy number until other
genetic changes have occurred. Precursor lesions suffering a
second hit in TP53 may have limited time for genetic
adaptation before accumulating a catastrophic mutation load.
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This window of heightened fragility could be decisive for the
different fates of KAs and SCCs. The presently observed
differences between average aberration values in KAs and
SCCs with or without copy number loss of the TP53 region
might be interpreted on this background. We can only
speculate that SCCs with TP53 loss have passed the window
and adapted to the genomic instability, whereas KAs with
TP53 loss have not. These KAs will then regress because of
new deleterious mutations to which they are not adapted.
However, our array CGH analysis cannot detect copy neutral
loss of heterozygosity and, thus, cannot further elucidate the
hypothesis that TP53 mutations can have different effects
depending on the timing relative to other genetic changes
(Durinck et al., 2011).
If we assume that KA and SCC are biologically separate
lesions with different pathogenetic pathways, how do we
explain the presence of overlapping genetic imbalances
detected by array CGH? First of all, many, if not most, of the
aberrations detected are probably without influence on tumor
progression and apoptosis/cell death. Second, it is well
known that sun exposure through UV irradiation is important
for the development of KAs and SCCs. Thus, many of the
overlapping aberrations may be due to DNA damage caused
by the common influence of UV. Considering the suggestion
that SCCs may develop with low frequency in KAs of elderly
persons (Weedon et al., 2010b), some overlap of genetic
aberrations may also be expected in some cases. The
observation that genetic aberrations are more numerous in
SCC than in KA may cause abrogation of many pathways in
SCC that are intact in KA, allowing apoptosis and sponta-
neous regression of the latter.
Chromosome CGH and array CGH are screening methods
with the advantage that they allow for simultaneous detection
and mapping of amplified and deleted chromosomal regions
of the entire genome of tumors in one single hybridization
(Kallioniemi et al., 1992; Pinkel et al., 1998). Limitations are
that balanced aberrations, such as translocations and inver-
sions, cannot be detected, and that the hybridization target
(chromosomes/arrays of BAC clones representing the relative
genomic sequences) limits the resolution of the methods.
However, array CGH data are significantly contributing by
suggesting genomic regions of interest for further search for
genes of importance for tumor classification before massively
parallel sequencing of captured regions or whole tumor
genomes is becoming practically feasible.
MATERIALS AND METHODS
Patients
A total of 132 KAs and 29 SCCs from the skin were collected in the
period from1995 to 2004. Among them, 126 KAs and 18 SCCs were
from patients consulting the Departments of Dermatology, Surgery
and Plastic surgery at Rikshospitalet, University of Oslo. DNA
extracted from lesions of 17 patients, 6 with KAs and 11 with SCCs,
were kindly provided from Center for Cutaneous Research,
University of London UK. DNA from these lesions, and from those
collected at Rikshospitalet, University of Oslo, was analyzed by
CGH as previously reported (Clausen et al., 2006). There was
sufficient remaining DNA from 98 KAs and 22 SCCs from this
material to allow further analysis by array CGH. The project was
approved by the ‘‘Regional committee for medical research ethics
Sothern-Norway (REK Sør)’’. The project number is S-06158. All patients
gave written, informed consent in adherence with the Declaration
of Helsinki Principles. The corresponding information of the histo-
pathological evaluation and HPV analysis for the 120 samples is
provided in ‘‘Supplementary Materials and Methods online.’’ The
summary of the clinicopathological description for the 98 KAs is
presented in Supplementary Table S1 online.
Array CGH and related data analysis
The array CGH analysis was performed as previously described
(Li et al., 2008, 2009). The detailed information of experimental
work and data analysis is provided in ‘‘Supplementary Materials and
Methods online.’’
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